3.4.24.75	analysis	improvement of lipid extraction of staphylococcal cells	695804	
3.4.24.75	diagnostics	detection of Staphylococcus aureus	695804	
3.4.24.75	food industry	antistaphylococcal agent	695804	
3.4.24.75	medicine	a bone morphogenetic protein 2-loaded lysostaphin-delivering hydrogel simultaneously prevents Staphylococcus aureus infection and repairs nonhealing segmental bone defects in the murine radius	755399	
3.4.24.75	medicine	application as effective antibiotic drug against infections with Staphylococcus aureus	670123	
3.4.24.75	medicine	enzyme-functionalized gold and silver nanoparticles are an antibacterial platform for combating methicillin-resistant Staphylococcus aureus bacterial infections	754815	
3.4.24.75	medicine	lysostaphin can be used in combination with clarithromycin for the eradication of Staphylococcus aureus biofilms with a minimal biofilm eradication concentration reduction of 9 and 6fold dilutions on meticillin-resistant S. aureus and meticillin-susceptible S. aureus, respectively	719602	
3.4.24.75	medicine	lysostaphin can be used potentially as a topical disinfectant or decolonizing agent against methicillin-resistant Staphylococcus aureus infection on on human skin prior to operations. The combination is significantly more effective than treatment with ranalexin or lysostaphin alone, overview	708898	
3.4.24.75	medicine	lysostaphin exerts high levels of activity against antibiotic-resistant strains of Staphylococcus aureus	733114	
3.4.24.75	medicine	lysostaphin has potential for use as an antistaphylococcal agent for treatment of infections caused by antibiotic-resistant strains of Staphylococcus aureus	718632	
3.4.24.75	medicine	lysostaphin is a therapeutic agent for methicillin-resistant Staphylococcus aureus pneumonia	733464	
3.4.24.75	medicine	lysostaphin is an antistaphylococcal agent. The enzyme is efficacious in the treatment of bovine mastitis caused by staphylococci	720624	
3.4.24.75	medicine	lysostaphin is an effective treatment as well as prophylaxis for Staphylococcus aureus biofilms on indwelling catheters	708895	
3.4.24.75	medicine	lysostaphin is useful in treatment of neonatal Staphylococcus aureus infection, overview	683082	
3.4.24.75	medicine	lysostaphin, in combinantion with the antibiotic ranalexin, is effective against wound or systemic infections caused by meticillin-resistant Staphylococcus aureus. The combination is significantly more effective than treatment with ranalexin or lysostaphin alone. Ranalexin and lysostaphin can be incorporated in wound dressings for the prevention and treatment of topical Staphylococcus aureus infections	708742	
3.4.24.75	medicine	lysostaphin-functionalized cellulose fibers show activity against Staphylococcus aureus in an in vitro skin model (HaCaT keratinocyte) with low toxicity toward keratinocytes, suggesting good biocompatibility for these materials as antimicrobial matrices in wound healing applications	719034	
3.4.24.75	medicine	potential therapeutic agent against antibiotic-resistant Staphylococcus aureus infections	695804	
3.4.24.75	medicine	staphylococcal disease pathogenesis	668814	
3.4.24.75	medicine	the enzyme can be used in life-threatening infections, such as endocarditis to increase the early in vivo activity of the antibiotics, and to prevent the emergence of linezolid resistant mutants	753949	
3.4.24.75	medicine	the enzyme is a potential antimicrobial agent for Staphylococcus aureus infections	-, 755476	
3.4.24.75	medicine	the enzyme is used against established staphylococcal biofilms as an alternative to bovine mastitis control	753987	
3.4.24.75	medicine	therapeutic agent for the treatment of Staphylococcus aureus infections	667220	
3.4.24.75	medicine	treatment of staphylococcal infections	669118	
3.4.24.75	additional information	antistaphylococcal agent in clinical laboratories	695804	
3.4.24.75	pharmacology	lysostaphin is useful for treatment for systemic Staphylococcus aureus infection in a mouse model	683596